Articles tagged with Breast Cancer Cells
Researchers found that the gene ZBP1 is silenced in metastasizing breast cancer cells due to a methyl group attachment, leading to increased cell migration and proliferation. The study suggests potential drug targets for preventing metastasis and may help predict breast tumor outcomes by identifying signs of ZBP1 silencing.
Researchers at UNC identified the p18 gene as a potential cause of luminal-type breast cancers, which account for 70-80% of all cases. The study found that defects in this gene lead to uncontrolled cell growth and cancer.
Research at Memorial Sloan Kettering Cancer Center identifies three genes mediating breast cancer's spread to the brain. COX2 and HB-EGF prime cells for entrance, while ST6GALNAC5 enables passage through the blood-brain barrier.
A novel gene called DEAR1 is associated with increased risk of local recurrence in young women with breast cancer. The discovery could lead to a new prognostic marker and guide treatment decisions.
Scientists at Johns Hopkins discovered that cell-to-cell contact revs up microRNA production, a key regulator of gene expression. The study found that physical contact is the critical factor influencing microRNA abundance, with increasing cell density leading to increased microRNA production in all tested cell lines.
Researchers have identified a key molecule called Liar that leads other molecules into the nucleus of blood cells, offering a potential treatment for cancer. A cellular enzyme known as Lyn has also been found to 'turn on' blood cell development, highlighting a new target for cancer therapy.
Researchers have identified two potential new targets in the fight against prostate cancer: 'cold shock' proteins that can be turned down through genetic techniques to weaken cancer cells, and higher bone density in men which may increase their risk of developing prostate cancer. Additionally, children with kidney stones are more likel...
The American Cancer Society has awarded 143 national research and training grants totaling over $51 million to investigators at 83 institutions nationwide. The grants support groundbreaking research into the molecular genetics, biochemistry, and cell biology of cancer.
Researchers found that lymphocytes, a type of immune system cell, produce the inflammatory protein RANKL when breast cancer cells are present. This leads to increased lung metastases. Blocking RANKL can halt cancer progression and may be a potential target for drug therapy.
A study at Duke University Medical Center has led to the development of a new technique that uses light scattering to determine whether chemotherapy is working. The method, called angle-resolved low coherence interferometry, measures changes in cellular structure following treatment with chemotherapeutic agents.
Researchers at University of Texas M. D. Anderson Cancer Center found that overexpressing PEA-15 in breast cancer grafts in mice resulted in nearly undetectable tumor levels after 35 days. This suggests PEA-15 as a new, important target for therapy.
Researchers at GUMC found that high levels of cholesterol in breast cancer cells may promote tamoxifen resistance. Inhibiting cholesterol production with statin drugs or new agents may restore sensitivity to the drug. The study suggests a potential new direction for treating ER+ invasive lobular breast cancer.
FAK coordinates movement of migrating cancer cells by balancing the number of invadopodia that create a path for migration and the number of focal adhesions that hold the cell back. In its absence, breast cancer cells sprout extra invadopodia and form large, sticky focal adhesions.
Researchers discovered that naturally fluorescent molecules like NADH can be used to detect cancer cells. The team developed a non-destructive method to measure NADH levels in live cells, which could help differentiate between normal and cancerous cells at early stages of tumor progression.
Researchers found that Muc4 promotes release of breast cancer cells from primary tumor, allowing them to survive and resist treatment. The study suggests that targeting Muc4 could lead to new treatments for breast and potentially other cancers.
A new test for metastasis could help doctors precisely identify which patients should receive aggressive therapy, sparing those at low risk from unnecessary treatment. The test detects the presence of a tumor microenvironment that predicts breast cancer spread.
Researchers at Johns Hopkins University developed a lab-on-a-chip device that can study cell detachment, a critical step in cancer metastasis. The device helps understand the molecular mechanisms behind cancer cells' ability to break free from tissue, which could lead to better therapies.
Researchers at Brown University have created a twin nanoparticle that specifically targets Her-2-positive breast cancer cells, releasing chemotherapy drugs into the infected cells. The system successfully killed up to 80% of cancer cells in laboratory tests.
Researchers at Baylor College of Medicine identified three small molecules that block the activity of Stat 3, a key enzyme in cancer cell survival. The compounds showed promise in inducing programmed cell death in breast cancer cells, offering new hope for cancer treatment.
Scientists have created unique microenvironment microarrays that reveal how adult stem and progenitor cells develop in a woman's breast. They found that the ultimate fate of these cells depends on signals from multiple microenvironments, suggesting a promising pathway for beneficial therapies.
Researchers identified proepithelin as a protein that encourages cell growth and migration in prostate cancer cells, especially androgen-independent ones. Proepithelin overexpression may serve as a clinical marker for prostate cancer diagnosis and a therapeutic target.
Researchers found that gene expression profiles differed between tumor samples from patients who had taken vitamin E, selenium, or both supplements compared to those on placebo. The study provides insight into the effects of preoperative supplement use on prostate cancer gene expression, a potential area for future investigation.
A study by Boston Children's Hospital researchers has identified lipocalin 2 as a protein that triggers the epithelial to mesenchymal transition in human breast cancer cells, increasing invasiveness and metastasis. The protein is detectable in urine samples, suggesting it may be used for prognostic testing.
Recent studies by Cornell researcher Rui Hai Liu found that fresh apple extracts significantly inhibited the size of mammary tumors in rats, with greater inhibition seen at higher doses. The findings highlight the potential health benefits of consuming more fruits and vegetables, including apples, to reduce breast cancer risk.
Researchers found that breast cancer cells can be made to express a transporter, allowing pyruvate to enter and induce cell death. The study aims to develop a new therapeutic target for fighting breast cancer.
Researchers have designed intelligent molecules that can recognize diseased cells, such as cancer cells, and trigger cell death only in their presence. This approach aims to reduce nonspecific side effects and improve therapeutic accuracy.
Researchers at Burnet Institute develop a potential new treatment for prostate cancer using a monoclonal antibody targeting the PIM-1 molecule, which plays a critical role in cell survival and proliferation. Laboratory models show significant inhibition of cancer cell growth, paving the way for clinical trials.
Cancer stem cells are more resistant to radiation due to a protective pathway that shields normal stem cells from DNA damage. By blocking this pathway, cancer stem cells become more susceptible to killing by radiation.
Researchers have discovered a new class of compounds that selectively inhibit protein phospholipase D (PLD), an enzyme linked to multiple human cancers. The inhibitors block invasive breast cancer cell migration and could be used as antimetastatic agents.
Researchers at Duke University have developed a new technology that can detect how cancer cells respond to chemotherapy in just hours, rather than weeks. This allows for quicker diagnosis and potentially more effective treatment.
Researchers at UC San Diego have developed an automated image screening process to distinguish breast cancer cells from normal cells. The technique, which uses computer software and microscopy, has shown promise in correctly identifying invasive breast cancer cells in 83% of tumor specimens.
University of Michigan researchers are using mathematical modeling to develop a more complete understanding of how cancer develops and interacts with its environment. This approach has led to new insights into the complex signaling pathways involved in cancer growth and metastasis.
A new study has identified certain patient and tumor characteristics that may indicate which breast cancer patients are at high risk of developing contralateral breast cancer. These include histologic invasive characteristics, multiple quadrants affected, and a high Gail risk score or age over 50 at diagnosis.
Researchers at Tel Aviv University have developed a nano-sized medical submarine that can target specific cells and deliver effective drugs to kill cancer cells and eradicate faulty proteins. The technology uses RNAi compounds and aims to treat various pathologies, including cancer, inflammation, and neurodegenerative diseases.
Canadian researchers have identified a new protein, ARF1, that plays a critical role in breast cancer cell growth and tumour spread. Targeting this protein with drug therapy may provide hope to women with invasive breast cancers.
A new study published in the Journal of Prosthodontics found that the absence of Human calmodulin-like protein (CLP) in oral epithelial cells may indicate oral cancer. The researchers used staining to compare CLP expression in normal and cancerous tissues, revealing a significant decrease or complete lack of CLP in malignant regions.
Researchers at Stanford University School of Medicine have discovered that metastatic cancer cells use a protein called lysyl oxidase (LOX) to target specific organs. By blocking LOX expression, the cells' migration and invasion can be prevented, offering a potential new approach to treating human disease.
Research suggests cisplatin ototoxicity is due to higher platinum concentration in inner ear, while high insulin levels are an independent risk factor for breast cancer. Studies found significant correlations between fasting insulin and increased breast cancer risk.
Researchers discovered that compounds like sulforaphane inhibit cell proliferation and kill precancerous cells, similar to anticancer drugs. This finding suggests that consuming cruciferous vegetables like broccoli may help prevent breast cancer.
Researchers discover that polyphenols in extra-virgin olive oil drastically suppress the overexpression of the cancer gene HER2 in human breast cancer cells. The findings suggest a safe platform for designing new anti-breast cancer drugs.
Researchers at the University of Rochester have designed a gene that produces a thousand times more protein in cancer cells than in healthy cells. This new approach allows for the insertion of 'self-destruct' codes, forcing cancer cells to kill themselves while healthy cells remain unaffected.
Scientists use a special glass 'window' to visualize individually-labeled tumor cells as they move through the body's microenvironments. The technique allows researchers to identify critical interactions driving intravasation and develop microenvironment-specific drugs.
A new breast imaging technology, BSGI, has been shown to detect additional lesions in women with suspicious mammography results. The study found that BSGI identified an additional suspicious lesion in 29% of women and 36% of those who underwent biopsy as cancerous.
A University of California, Berkeley study has identified a key enzyme target for indole-3-carbinol, a broccoli compound that slows down rapidly advancing breast cancer cell growth. The research provides a basis for designing more effective anti-cancer drugs and could lead to breakthroughs in treating prostate tumors.
A team of scientists at Cold Spring Harbor Laboratory discovered that the protein Scribble regulates breast cancer by controlling cell polarity. In normal cells, Scribble allows duct-like structures to form and resist cancer formation.
A meta-analysis of 15 randomized controlled trials found that bevacizumab increases the risk of venous thromboembolism by 33% compared to controls. The risk is highest for patients with colorectal cancer, with an incidence rate of 19.1%.
A study by UNC researchers found that palladin, a protein expressed mostly in invasive breast cancer cells, plays a crucial role in their ability to migrate and spread. Knocking down palladin expression reduced the ability of breast cancer cells to metastasize.
Research finds that PEA-15 protein forces ovarian cancer cells to eat themselves, leading to increased median survival time. High levels of PEA-15 are linked to improved patient outcomes and may offer a new dimension for targeting ERK in cancer therapy.
Researchers have discovered a previously unknown cell pathway that drives a lethal subtype of breast cancer, disproportionately affecting African American women. The study may lead to the development of new targeted therapies for this aggressive cancer type.
Fox Chase researchers create bispecific antibody ALM that attacks two signaling proteins on breast cancer cell surfaces, halting growth. The molecule could deliver therapeutic drugs directly to cancer cells or aid in early detection.
Breast cancer cells closer to blood vessels are more aggressive and directed in their invasiveness, according to a new study. The research provides detail on how cancer cells invade surrounding tissue and reach blood vessels, offering insights into early stages of metastasis.
A recent study discovered that the Overexpressed in Lung Cancer 1 (OLC1) gene is consistently expressed at high levels in most lung cancers, particularly in smokers. OLC1 overexpression was also shown to induce tumor formation in tissue culture cells and mouse models of lung cancer.
Researchers aim to identify undiscovered genes involved in early breast cancer stages by studying genetic information from thousands of breast samples. The technique could help monitor women at higher risk due to inherited gene defects, reducing mortality from breast cancer.
Mantle cell lymphoma cells rely on heat shock protein 90 to maintain their rapid growth. Researchers are using inhibitors to block this process, causing stress in the cells' machinery. The goal is to trigger apoptosis in cancer cells.
Researchers at Georgetown University Medical Center have found a novel way in which breast cancer cells become resistant to tamoxifen, a world's largest-selling breast cancer prevention and treatment drug. The study suggests that the gamma estrogen-related receptor subtype may be stimulating cancer growth.
A study published in Cancer Research found that nicotine can promote breast tumor growth and metastasis by binding to nicotinic receptors on mammary cells. The researchers also discovered that nicotine potentiates tumorigenesis when combined with other factors.
A University of Cincinnati study finds that bisphenol A (BPA) induces proteins protecting cancer cells from chemotherapy's toxic effects. Researchers suggest BPA may be a contributing factor to chemotherapy resistance in cancer patients.
The Notch pathway plays a crucial role in regulating breast stem cell fate, controlling both stem cell number and the production of luminal cells. Errant activation of Notch leads to uncontrolled growth of luminal precursors, resulting in breast tumour formation.
Researchers at Baylor College of Medicine found a solution to the high cost of commercial media for 3D cell cultures using chicken egg whites. The process enables normal and cancer cells to be grown in three dimensions, allowing scientists to study cell signaling and tumor microenvironments.
Researchers have discovered how the Mre11 protein bridges diverse molecular architectures at DNA breaks, resolving paradoxes about its function. The findings offer new strategies for targeting this enzyme in cancer therapies, particularly when combined with other inhibitors of DNA repair.